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Abstract
Circulating small RNAs, including miRNAs but also isomiRs and other RNA species, have
the potential to be used as non-invasive biomarkers for communicable and non-communica-
ble diseases. This study aims to characterize and compare small RNA profiles in human bio-
fluids. For this purpose, RNA was extracted from plasma and breast milk samples from 15
healthy postpartum mothers. Small RNA libraries were prepared with the NEBNext® small
RNA library preparation kit and sequenced in an Illumina HiSeq2000 platform. miRNAs, iso-
miRs and clusters of small RNAs were annotated using seqBuster/seqCluster framework in
5 plasma and 10 milk samples that passed the initial quality control. The RNA yield was 81
ng/mL [standard deviation (SD): 41] and 3985 ng/mL (SD: 3767) for plasma and breast milk,
respectively. Mean number of good quality reads was 4.04 million (M) (40.01% of the reads)
in plasma and 12.5M (89.6%) in breast milk. One thousand one hundred eighty two miR-
NAs, 12,084 isomiRs and 1,053 small RNA clusters that included piwi-interfering RNAs
(piRNAs), tRNAs, small nucleolar RNAs (snoRNA) and small nuclear RNAs (snRNAs) were
detected. Samples grouped by biofluid, with 308 miRNAs, 1,790 isomiRs and 778 small
RNA clusters differentially detected. In summary, plasma and milk showed a different small
RNA profile. In both, miRNAs, piRNAs, tRNAs, snRNAs, and snoRNAs were identified, con-
firming the presence of non-miRNA species in plasma, and describing them for the first time
in milk.
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Introduction
Discovery of novel biomarkers for early detection and improved prognosis in non-communi-
cable and infectious diseases is a research priority. A good biomarker should be suitable to
diagnose the disease, predict its progression or regression, or to monitor the outcome after
treatment and, ideally, should be easily obtained with minimum invasion [1].
Promising classes of molecular biomarkers are small RNAs, and special attention has been
given to microRNAs (miRNAs) [2]. miRNAs are short (21–23 nt), single-stranded, non-coding
RNAs that regulate gene expression and play essential roles in fundamental biological processes.
Recent studies have shown the involvement of miRNAs in various aspects of major chronic dis-
eases including bronchial asthma and diabetes, as well as in regulation and induction of senes-
cence, brain function and cancer [3–8]. Changes in miRNA expression can be triggered by
environmental factors such as exposure to pesticides, heavy metals, air pollution, bisphenol A
and cigarette smoking [9, 10]. The content of miRNAs is also influenced by host-pathogen
interactions, as has been shown for bacteria, viruses and apicomplexan parasites [11].
miRNAs can be actively secreted to circulation packaged in microvesicles, exosomes, or
associated to RNA-binding proteins, such as Ago2, but cell death or apoptosis can also release
miRNAs into the circulation [9]. Their resistance to pH variations, their stability during long
term storage and repeated freeze-thaw cycles [12], and the fact that they can be detected in cir-
culation but released by distant organs constitute them as potential non-invasive biomarkers
to monitor the body’s pathophysiological status. However, besides some particular cases where
circulating miRNAs have been tested in clinical trials [13, 14], there is lack of reproducibility
between studies, highlighting the need of a standardization of laboratory and bioinformatic
methods [15].
Next generation sequencing (NGS) allows not only the quantification of known miRNAs,
but also the identification and quantification of novel miRNAs, isomiRs (miRNA variants)
[16], and other small RNA species that can be functionally relevant in diseases and therefore
used as potential disease biomarkers [17, 18]. However, only few studies have investigated cir-
culating non-miRNA small RNAs, focusing on plasma [19, 20], urine and saliva [21] Although
there is an extensive literature on the potential effects of breast milk miRNAs on offspring
development [22–24], none of these previous studies has evaluated non-miRNA small RNAs
in human milk.
The vast majority of small RNA bioinformatic tools are designed for the analysis of miR-
NAs. They usually discard multi-mapping reads derived from non-coding RNAs with duplica-
tion events in the genome, or alternatively, they count them several times or split the reads in
all the genomic positions, which bias the estimations. Recently, Pantano et al. developed
SeqCluster, a method for the accurate quantification of small RNAs, based on the estimation
of clusters of highly similar sequences irrespective of their genomic annotation [25, 26].
This study aims to characterize miRNAs, isomiRs and small RNA clusters in plasma and
milk as well as compare their profiles. For this purpose, miRNAs, isomiRs and small RNA clus-
ters were analysed in samples collected from 15 healthy women at 24-72h post-delivery. In
order to facilitate future studies in the field, detailed information on sample collection, pro-
cessing and bioinformatics analysis is given.
Materials and methods
Study population
Fifteen Spanish healthy volunteers were enrolled in the study. Exclusion criteria were as fol-
lows: HIV, Hepatitis B or Hepatitis C positivity; severe preeclampsia; gestational diabetes and
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preterm delivery (<37 weeks of gestation). Basic demographics of the women and data about
gestation and delivery were collected. Peripheral blood was collected at 0–48 h post-partum
for 15 participants; and breast milk was collected at 48–72 h post-partum for 10 of the partici-
pants. Participants signed an informed consent and protocols were approved by the Hospital
del Mar and Hospital Clinic (Barcelona, Spain) ethical committees.
Collection and pre-processing of samples
Plasma. Twelve mL of peripheral blood were collected in VACUETTE1 EDTA Tubes
(K3EDTA vacutainers) (Greiner Bio-One, Cat No.: 456038). EDTA blood tubes were gently
mixed by inverting 10 times and stored at 4˚C upright until centrifugation. Plasma separation
was performed by centrifugation of blood samples in horizontal rotor for 10 minutes at 2000 x
g at 4˚C. A second centrifugation at 16,000 x g for 15 minutes at 4˚C, was performed to elimi-
nate any cell debris. Plasma was transferred to a new RNase-free cryotube avoiding the collec-
tion of any cell debris and stored at -80˚C.
Plasma haemolysis was evaluated by spectrophotometry using a NanoDrop ND-2000
equipment (Thermo Fisher Scientific). Absorbance at 414 nm of 0.2 was set as cut-off haemo-
lysis as described before [27].
Milk. Fifteen mL of breast milk were extracted using an electric pump (Medela, Cat
No.:008.0176) following manufacturer’s instructions and transferred to a 100 mL sterile
RNase-free recipient. Milk was kept in ice and vortexed gently before centrifugation at 2000 x
g for 10 minutes at 4˚C to remove milk fat globules, cells, and large debris. Immediately after
carefully transferring, supernatant was carefully transferred into new 2 mL RNase-free tubes, a
second centrifugation at 16,000 x g for 15 minutes was performed at 4˚C to remove residual
fat, cell debris and the casein fraction. Skim milk, avoiding fat or cells, was transferred into 2.5
mL cryotubes and stored at -80˚C.
RNA extraction, quantification and quality control
Small RNAs were extracted using the miRNeasy Serum/Plasma kit (Qiagen, Cat No.: 217184)
with minor modifications. RNA extraction was performed from at least 3 mL of plasma and
milk. One mL of biofluid was filtered per each column and washed two times with ethanol
80% before elution. Each sample was measured for RNA quantity using Fluorometric quantifi-
cation (Qubit™ 2.0 Fluorometer, Thermo Fisher Scientific) with the Qubit miRNA assay
(Thermo Fisher Scientific) and for integrity and quality using two different methods: spectro-
photometer (NanoDrop™ 1000, Thermo Scientific) and electrophoresis and flowcytometry
(Agilent RNA 6000 pico chip and Agilent 2100 Bioanalyzer, Agilent Technologies).
Library preparation and sequencing
Libraries were prepared using the NEBNext1 Small RNA Library Prep Set for Illumina1
(Multiplex Compatible) (NEB, Cat No.: E7330) following manufacturer instructions and using
150ng of RNA obtained from plasma samples and 500 ng from milk. Library size selection was
done using acrylamide gels. Quality and concentration of cDNA libraries was checked, and
finally groups of 13–20 samples were pooled at the same concentration before sequencing in
an Illumina HiSeq2000 Sequencing System (50 nt, single read).
Bioinformatic and statistical analyses
Quality control. The bioinformatic pipeline consisted of several steps (S1 Fig). An initial
quality control (QC) was conducted using FASTX-Toolkit and FastQ Screen. After adaptor
Circulating small RNAs in human biofluids
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removal, reads with the following features were removed: 1) Reads<18nt, 2) Mean PHRED
scores< 30, and 3) Low complexity reads based on mean score of the read. Then, QCed reads
were mapped to miRNAs, and miRNA complexity was estimated as the number of miRNA
genes that are observed as a function of the number of miRNA reads.
Identification and quantification of small RNAs. Sequences fulfilling QC were used as
the input for the seqBuster/seqCluster tool that retrieves three matrices of counts: i) miRNA,
ii) isomiRs, and iii) small RNA clusters [25, 28]. In order to detect miRNAs and isomiRs, reads
were mapped to hairpins released from miRBasev21 using miraligner allowing one mismatch
[28]. Sequences mapping ambiguously to several positions of the genome were filtered out.
Only isomiRs with 3’ or 5’ trimming or 3’ addition modifications are kept in the result files.
isomiRs with one nucleotide substitution are not reported due to the difficulty of linking them
unambiguously to a particular miRNA. IsomiR naming followed the miRTop project’s recom-
mendations (http://mirtop.github.io/). IsomiR names can be merged with isomiR sequences
using a GFF3 format file provided on GEO. In parallel, sequences were mapped to hs37d5
using bowtie [29], and hotspots (sets of overlapping sequences according to their position in
the genome) were detected. Hotspots sharing any sequence were grouped in primary clusters.
Then, a recursively heuristic algorithm based on reduction and cluster correction was applied
to the ones sharing over 60% of the sequences. These were annotated to different RNA species
using miRBase v20 [30], refGene (RefSeq genes), wgRna (CD and H/ACA Box snoRNAs and
miRNAs from Weber and Griffiths-Jones), rmsk (Repeating elements created using Repeat-
Masker) and tRNA from University of California Santa Cruz (UCSC) genome browser (hg19)
[31], and piR_hg19_v1.0 from the regulatoryrna database (www.regulatoryrna.org) [32]. Clus-
ters can be considered as unique units of transcription, regardless of their annotation to one or
multiple positions in the genome (irrespective of their genomic origin).
Raw FASTQ files, quality controlled unnormalized counts, metadata and a GFF3 format
file with isomiR annotation can be downloaded from Gene Expression Omnibus (GEO):
GSE107524.
Normalization and differential expression. Normalization and differential expression
was performed with the R package DESeq2 v.1.10.1 (R version 3.3.2) [33]. DESeq2 performs
an internal normalization where geometric mean is calculated for each gene across all sam-
ples (scaling factor method) The impact of main technical and demographic/biological vari-
ables on normalized counts was explored through Principal Component Analysis (PCA) and
dendrograms implemented within the FactoMineR R package [34]. Differential expression
was assessed with negative binomial generalized linear models adjusting for multiple testing
with the False Discovery Rate (FDR) method [35]. All models considered biofluid as the
independent variable and were adjusted for subject as a fixed effect. In addition, a sensiti-
vity analysis considering only paired samples was performed and results did not change
substantially.
Milk samples presented systematically higher sequencing depth than plasma samples. As
sensitivity analyses, we repeated the miRNA differential analyses with different filtering
approaches. Our main analysis used DESeq2 to filter out features having little chance of show-
ing significant evidence as they contain outliers or low mean normalized counts. Second, to
avoid comparison of miRNAs not detected due to the lower sequencing depth in plasma sam-
ples, an initial filtering of miRNAs present in <80% of the samples and with <10 reads was
done. Finally, ten random milk and plasma subsamples of 0.2M miRNA reads each (the mini-
mum in plasma samples) were obtained and analysed. P values of each of the 10 differential
analysis were combined using simes test [36], from mppa v.1.0 (eprint arXiv:1408.3845) in R
(3.3.2).
Circulating small RNAs in human biofluids
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Results
Study population and sample collection
Fifteen healthy volunteer mothers were enrolled in the study during 24-72h post-delivery.
Main characteristics of the mothers are found in Table 1. Mean age of the participants was
32.9 years. Forty percent of them were primiparous and only one of them smoked during preg-
nancy. One third of the participants were born in Spain, one third in Asia and the rest were
from Morocco and South America. Plasma samples were collected for all 15 women, while
milk was available for 10 of them.
RNA extraction and quality control
The average amount of RNA extracted from plasma and milk samples was 81.14 ng/mL (stan-
dard deviation, SD 40.92) and 3,984.85 ng/mL (SD 3,766.97), respectively (S1 Table). In the
Bioanalyzer plot, all biofluids showed a peak between 25 to 200 nucleotides which corre-
sponded to the expected size for small RNAs (S2 Fig). No peaks were detected at 18S and 28S
in plasma, whereas a peak was observed in half of the milk samples, suggesting potential con-
tamination with cellular RNA.
Quality control
The mean number of reads obtained for each biofluid was similar: 13.96 million (M) in plasma
and 13.87 M in milk. However, the average proportion of good quality reads was 89.58% in
milk, and only 40.01% in plasma (Table 2 and S2 Table). Three point ninety seven percent and
35.72% of the raw reads mapped to miRNAs in plasma and milk, respectively. Only samples
with>2M of good quality reads of which>0.2 M mapped to miRNAs were considered for fur-
ther analysis (10 milk and 5 plasma samples).
miRNAs
Total number of miRNAs detected with>1 count were 1,182: 1,002 in milk [456 with a mean
abundance of>10 reads per million (RPM)] and 824 in plasma [271 with a mean abundance
of>10 RPM]. Ten miRNAs comprised >70% of the expression in each biofluid (Fig 1, S3
Table). miRNA complexity was quite heterogeneous among samples, even among samples
from the same biofluid, and tended to be higher in milk than in plasma (S3 Fig). Samples clus-
tered by biofluid and not by subject (Fig 2). Data did not cluster by technical factors (time to
Table 1. Main characteristics of study participants.
Variable Summary
Age (years); mean (range) 32.93 (23–40)
Parity; n (%)
Primigravidae 6 (40%)
Multigravidae 9 (60%)
Region of origin; n (%)
Spain 5 (33.3%)
Asia 5 (33.3%)
Morocco 2 (13.3%)
South America 3 (20.1%)
Tobacco smoking during pregnancy; n (%)
Yes 1 (6.7%)
No 14 (93.3%)
https://doi.org/10.1371/journal.pone.0193527.t001
Circulating small RNAs in human biofluids
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storage, RNA extraction date, library preparation date, sequencing run and lane) or demo-
graphic/biological variables (age, region of origin, and parity) (S4 Fig).
At 5% FDR, 308 miRNAs showed different levels between biofluids [126 (40.91%)
milk> plasma] (Table 3 and S4 Table). Among the 112 miRNAs found in >80% of the sam-
ples and with>10 counts, 87 of them showed statistically significant differences between bio-
fluids (66 milk > plasma). Seventy-four out of the 87 miRNAs overlapped with the ones
detected in the main analysis (S7 Fig).
Table 2. Quality control and mapped reads to miRNAs [mean and (SD)], by biofluid.
Plasma Milk
(N = 15) (N = 10)
Total reads; millions (SD) 13.96 (16.71) 13.87 (8.23)
Quality filtered; millions (SD) 9.82e-3 (9.75e-3) 6.33e-3 (1.98e-3)
Complexity filtered; millions (SD) 1.40e-4 (1.32e-4) 1.39e-4 (7.26e-5)
Size filtered; millions (SD) 9.92 (11.40) 1.36 (0.86)
Good quality readsa
Millions (SD) 4.04 (6.16) 12.52 (7.74)
% raw reads (SD) 40.01 (23.05) 89.58 (5.42)
miRNA
Millions (SD) 0.27 (0.44) 5.42 (4.88)
% raw reads (SD) 3.97 (4.36) 35.72 (12.40)
% QCed reads (SD) 8.92 (6.85) 40.02 (13.43)
N samples testedb 5 10
a Reads after filtering low quality, low complexity and size <18 nt.
b Number of samples tested in the downstream differential analysis of miRNAs, isomiRs and small RNA clusters
(>0.2M reads in miRNAs).
https://doi.org/10.1371/journal.pone.0193527.t002
Fig 1. Relative abundance of miRNA and small RNA clusters. (A, C) Plasma, (B, D) milk. The x-axis represents
miRNAs (A, B) or small RNA clusters (C, D) ordered according to their expression level and the y-axis represents the
abundance as percentage of reads (%) (average of all samples). Error bar shows SD.
https://doi.org/10.1371/journal.pone.0193527.g001
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To further confirm the results given the different sequencing depth of each biofluid, 10 ran-
dom subsamples of 0.2 M miRNA reads were obtained for each plasma and milk sample. The
total number of unique miRNA in the 10 milk subsamples was 534 (115 common to all milk
samples) and in the 10 plasma subsamples was 715 (100 common to all plasma samples). Sam-
ples were again classified by biofluid (S8 Fig). Two-hundred and fourteen miRNAs exhibited
different levels depending on the biofluid [72 (33.64%) milk> plasma]. One hundred and
eighty six overlapped with the results of the main analysis (S7 Fig, S4 Table).
isomiRs
Total number of isomiRs with >1 count was 10,541 in milk (1,798 with mean abundance of
>10 RPM) and 4,760 in plasma (1,376 with mean abundance of>10 RPM) (S5 Table). Some
Fig 2. Dendogram of samples according to their normalized miRNA levels (10 milk samples (M) and 5 plasma samples (P)).
Samples are classified by biofluid and not by individual as indicated by the squares.
https://doi.org/10.1371/journal.pone.0193527.g002
Circulating small RNAs in human biofluids
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miRNAs bear more than one modification type. In plasma, 3’ additions, 3’ trimming and 5’
trimming modifications represented 31.77%, 48.20%, and 20.03% of all editions, respectively.
In milk, distributions were rather similar (3’ additions: 34.04%, 3’ trimmings: 44.91%, and 5’
trimmings: 21.05%). Table 4 describes the distribution and abundance by biofluid of different
types of isomiRs, as combinations of 1, 2 or 3 modification types. The most common combina-
tions in terms of number of isomiRs were: 3’ addition + 3’ trimming (27.98% in plasma and
34.39% in milk) and 3’ trimmings (27.79% in plasma and 18.35% in milk). Regarding relative
Table 3. Differential levels of miRNAs by biofluid—top 10 ordered by p value.
A. Top ten higher in plasma
miRNA baseMean log2FC p value adjusted p value
hsa-miR-451a 26988.57 11.57 5.09e-62 3.59e-59
hsa-miR-122-5p 117899.75 13.14 9.14e-47 3.23e-44
hsa-miR-486-5p 531306.29 14.15 1.26e-42 2.96e-40
hsa-miR-4508 790.10 10.21 5.36e-38 9.47e-36
hsa-miR-134-5p 500.38 9.47 6.17e-24 8.71e-22
hsa-miR-363-3p 451.88 6.03 2.53e-21 2.98e-19
hsa-miR-584-5p 319.49 7.77 8.87e-21 8.95e-19
hsa-miR-150-5p 815.24 6.25 2.00e-20 1.66e-18
hsa-miR-370-3p 317.26 9.52 2.11e-20 1.66e-18
hsa-miR-127-3p 670.08 7.22 8.02e-20 5.66e-18
B. Top ten higher in milk
miRNA baseMean log2FC p value adjusted p value
hsa-miR-200b-3p 22349.79 -7.74 2.60e-19 1.67e-17
hsa-miR-30a-5p 90191.79 -5.59 1.34e-18 7.88e-17
hsa-miR-200a-3p 55145.39 -7.13 4.16e-18 2.26e-16
hsa-miR-200c-3p 31313.85 -7.34 7.23e-18 3.64e-16
hsa-miR-146b-5p 73258.87 -5.00 2.70e-17 1.27e-15
hsa-miR-200a-5p 2472.99 -8.19 4.87e-15 2.02e-13
hsa-miR-30b-5p 2335.32 -6.24 9.53e-14 3.54e-12
hsa-miR-141-3p 9204.94 -7.08 1.48e-13 5.24e-12
hsa-miR-193b-3p 797.36 -6.97 1.84e-13 6.18e-12
hsa-miR-30a-3p 5492.94 -5.51 2.22e-12 6.27e-11
Analysis was done with DESEq2. baseMean is the mean of normalized counts for all samples. log2FC is the log2 fold change between plasma and milk samples. Adjusted
p value by the Benjamini-Hochberg method.
https://doi.org/10.1371/journal.pone.0193527.t003
Table 4. Number and relative abundance of different types of isomiRs, as combinations of different editions, in milk and plasma.
Number of isomiRsa Relative abundance (%)b
Plasma (N = 4760) Milk (N = 10541) Plasma Milk
isomiR with different modifications: N % N % Mean SD Mean SD
3’ addition 549 11.53% 987 9.36% 21.75% 7.86 6.41% 1.24
3’ addition + 3’ trimming 1332 27.98% 3625 34.39% 8.11% 2.42 19.33% 6.98
3’ addition + 3’ trimming + 5’ trimming 406 8.53% 1358 12.88% 0.35% 0.20 0.95% 0.35
3’ addition + 5’ trimming 181 3.80% 489 4.64% 0.24% 0.07 0.26% 0.11
3’ trimming 1323 27.79% 1934 18.35% 66.89% 8.47 70.66% 8.46
3’ trimming + 5’ trimming 683 14.35% 1604 15.22% 1.76% 0.99 1.54% 0.15
5’ trimming 286 6.01% 544 5.16% 0.90% 0.41 0.85% 0.18
https://doi.org/10.1371/journal.pone.0193527.t004
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abundance, isomiRs with 3’ trimming changes accounted for around 70% of total reads in
both biofluids. They were followed by isomiRs with 3’ additions, in plasma, and by isomiRs
with a combination of 3’ trimmings + 3’ additions, in milk.
At a 5% FDR, 1,790 isomiRs (variants of 298 different miRNAs) showed different levels
between biofluids [1,266 (70.73%) milk> plasma] (S6 Table).
Small RNA clusters
In total, one thousand and fifty three small RNA clusters were identified in the 10 milk and 5
plasma samples. One thousand and three of them were found in milk with>1 count (930 with
mean abundance of>10 RPM), and 819 in plasma (648 with mean abundance of>10 RPM).
Only for descriptive purposes, clusters with multiple annotations were classified to one single
RNA class following this prioritization: miRNA, rRNA, tRNA, snoRNA, small nuclear RNA
(snRNA), vault RNAs (VTRNA), long non-coding RNA (lncRNA), piRNA, gene, and repeats.
The number and proportion of clusters in each RNA class by biofluid can be found in Table 5.
In both biofluids, more than 30% of the clusters identified were annotated to genes, and
around 20% to miRNAs. Milk samples showed a higher proportion of reads mapping to miR-
NAs (46.76%) and tRNAs (30.91%), whereas plasma had a higher proportion of reads in clus-
ters represented by piRNAs (32.03%), genes (6.25%), and repeats (40.57%) (Table 5). miRNA
clusters in plasma corresponded to 18.20% of the total number of reads. Around 6% and 3% of
the reads remained not annotated in plasma and milk, respectively.
Similarly to the miRNA analysis, the 10 most abundant clusters represented >75% of the
reads in each biofluid (Fig 1, S7 Table). In milk, a tRNA cluster (tRNA-Gly-GCC, tRNA-Gly-
CCC2,COLQ, VAC14, and several piRNAs) accounted for 21.67% of the reads, followed by
MIR148Awith 20.69%. In plasma, 37.94% were from a cluster that mapped to several piRNAs
and RXRB gene. The second most abundant cluster, with 21.04% of the reads, included
MIR486-1,MIR486-2, and ANK1gene. Abundance profile along precursor of these four clus-
ters is shown in S9 Fig.
The levels of 774 clusters were statistically significant different between plasma and milk
[291 (37.60%) milk> plasma] (Table 6 and S8 Table). Besides differently detected miRNAs,
Table 5. Number of clusters and abundance in milk and plasma.
Number of clusters Relative abundance (%)a
Plasma (N = 819) Milk
(N = 1,003)
Plasma Milk
Cluster class N % N % Mean SD Mean SD
miRNA 181 22.10 191 19.043 18.20 11.88 46.76 16.41
rRNA 5 0.61 6 0.60 0.01 0.01 0.01 0.00
tRNA 78 9.52 85 8.48 1.00 0.23 30.91 15.49
snoRNA 33 4.03 34 3.39 0.07 0.04 0.24 0.14
snRNA 3 0.37 4 0.40 0.03 0.03 0.01 0.01
VTRNA 3 0.37 3 0.30 0.01 0.01 0.01 0.01
lncRNA 14 1.71 19 1.89 0.36 0.20 0.03 0.01
piRNA 9 1.10 12 1.20 32.03 5.86 8.42 2.94
gene 259 31.62 421 41.97 6.25 2.80 0.93 0.32
repeat 108 13.19 97 9.67 40.57 36.66 10.02 3.44
not annotated 126 15.38 131 13.06 6.44 5.38 2.66 1.75
a Average of relative abundance of all samples (number of reads of each cluster class in a particular sample divided by total number of reads in that sample).
https://doi.org/10.1371/journal.pone.0193527.t005
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clusters of other RNA classes were identified. They included clusters mapped to genes (TSHZ2,
plasma>milk), tRNAs (tRNA-Trp-CCA-2-1, milk > plasma), VTRNs (VTRNA2-1, plasma >
milk), snoRNAs (SNORD95, plasma > milk), or lncRNAs (HOTAIR, plasma > milk). Their
profiles can be seen in S10 Fig. When considering isomiRs or small RNA clusters instead of
miRNAs, samples also grouped by biofluid (S5 and S6 Figs).
Discussion
In this study, we identified several species of small RNAs, including miRNAs, piRNAs, tRNAs,
snRNAs and snoRNAs in both plasma and breast milk. Their profiles were biofluid specific.
As the identification of circulating small RNAs depends on the quality of the biological mate-
rial, the quantification method and the bioinformatic pipeline, we discuss bellow the technical
aspects followed during this study that can potentially affect the results obtained.
RNA extraction and sequencing
The RNA extraction and sequencing yielded data of enough quality for all milk samples and 5
out of the 15 plasmas. Forty % of reads in plasma and 89.58% in milk passed the quality control
step, with only 3.97% and 35.72% mapping to miRNAs, respectively. RNA input for plasma
Table 6. Differential levels of small RNA clusters by biofluid—top 10 ordered by p value.
A. Top ten higher in plasma
Cluster id Cluster class annotation baseMean log2FC p value adjusted p value
141 miRNA MIR451B,MIR451Aa 27640.81 11.76 1.44e-48 1.53e-45
695 miRNA MIR122a, MIR3591 114740.42 13.24 3.05e-36 1.61e-33
815 miRNA MIR486-1a, MIR486-2a, ANK1 581529.14 14.32 6.79e-35 2.39e-32
114 miRNA MIR150a 878.09 6.47 3.93e-18 1.04e-15
362 gene TSHZ2, repeat 1745.85 8.87 1.41e-17 2.99e-15
671 miRNA MIR127a, RTL1 607.44 7.54 1.43e-16 2.51e-14
390 miRNA MIR363a 434.99 6.20 4.46e-15 5.89e-13
30 repeat Repeat 4220.07 8.31 7.15e-15 8.40e-13
314 gene ARHGEF38, repeat 3069.65 8.22 9.92e-15 1.05e-12
361 not annotated not annotated 1429.83 7.93 1.39e-14 1.23e-12
B. Top ten higher in milk
Cluster id Cluster class annotation baseMean log2FC p value adjusted p value
128 miRNA MIR200Ba 23506.88 -7.91 8.64e-16 1.30e-13
127 miRNA MIR200Aa 59945.49 -7.31 1.22e-14 1.17e-12
130 miRNA MIR200Ca, LOC105369635 31561.40 -7.42 2.74e-14 2.23e-12
963 miRNA MIR30Aa 98503.77 -5.61 1.19e-13 7.88e-12
943 miRNA MIR146Ba 76866.79 -5.01 1.40e-12 6.18e-11
659 miRNA MIR335,MeST 2261.74 -6.84 2.24e-12 9.47e-11
825 tRNA tRNA-Trp-CCA-2-1 1432.83 -6.70 1.64e-11 5.98e-10
794 tRNA tRNA-Asp-GTC-1-1, LOC643770 2532.81 -8.52 5.14e-11 1.65e-09
131 miRNA MIR141a, LOC105369635 9289.10 -7.18 7.28e-11 2.20e-09
849 tRNA tRNA-Val-TAC -1 2848.07 -5.87 1.58e-10 4.19e-09
Analysis was done with DESEq2. baseMean is the mean of normalized counts for all samples. log2FC is the log2 fold change between plasma and milk samples. Adjusted
p value by the Benjamini-Hochberg method
a Detected among the top 10 findings in the miRNA analysis.
https://doi.org/10.1371/journal.pone.0193527.t006
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and milk small RNA libraries were 150 ng and 500 ng, respectively, which respond to the dif-
ferent RNA quantity obtained for each biofluid. RNA yield is thus a key factor for the quality
of sequencing data.
In plasma, the lack of 18S and 28S peaks in the RNA patterns obtained with the Bioanalyzer
suggested the absence of RNA cell contamination. Indeed, plasma samples were centrifuged
twice in <3.5 h after blood collection and the spectrophotometer haemolysis values were
below 0.2, except for one sample. Given the low RNA yield obtained per mL of plasma (around
40 ng/mL), the addition of carriers during RNA extraction would be recommended [37].
In contrast, milk samples presented some signal at 18S and 28S, independently of whether
samples were centrifuged one or two times before storing. Milk samples also showed systemat-
ically higher RNA levels by mL of biofluid than plasma samples (around 50-times higher lev-
els). Given the higher amount of RNA obtained in milk and the presence of ribosomal RNA,
we suspect contamination with the cellular fraction during skim milk sample separation. How-
ever, other studies reported similar RNA yields for skim milk (around 4000 ng/mL) as ours,
and higher amounts in the milk fat and cellular fractions [38]. Contamination with cellular
RNA is one of the main issues in the use of circulating free small RNAs as biomarkers of dis-
ease [39]. Therefore, all the findings shown here, as well as in other publications, should be
interpreted considering this potential limitation.
Small RNA bioinformatic analysis
Currently, the analysis of miRNA sequencing data is quite straight forward. In contrast, differ-
ences of one or few nucleotides in isomiRs with respect to reference miRNAs and frequent
multicopy non-miRNA small RNAs in the genome impose several limitations to their bioin-
formatics analysis. To quantify small RNAs, we used SeqCluster, a tool that groups RNAs in
clusters based on their sequence similarity. RNA clusters are defined as unique transcriptions
units with potentially the same molecular function given their similar sequence, regardless of
their genomic location. For instance, tRNAs which are present in different copies in the
genome are clustered together. The reference databases and approach used in this study differ
from the pipeline followed in two of the most recent publications on circulating small RNAs:
Freedman et al. 2016 (ExceRpt, based on sRNABench) [19] and Yeri et al. 2017 (sRNABench)
[21]. In sRNABench, reads are first mapped to miRNA, and remaining reads are mapped to
other small RNAs using ENSEMBL 75. For isomiRs characterization, 3’ additions and 3’ and 5’
trimming editions were considered in the analysis, as there are strong evidences of their pro-
cessing [40–42]. In contrast, isomiRs with substitutions were discarded due to difficulty of
mapping them unambiguously.
Small RNAs in plasma
Ten out of the 824 miRNAs detected in plasma represented >70% of total number of reads
mapping to miRNAs. Other authors have also reported few miRNAs accounting for around
50% of the total number of sequencing reads [19, 43]. In agreement with Yeri et al. [21] hsa-
miR-486-5p was the most abundant miRNA in plasma (representing approximately 40% of
the miRNA reads). A bias towards this miRNA in samples prepared with the Illumina kit has
been reported in plasma-derived exosomes [20]. Ten and 8 of the 10 top miRNAs identified in
this study were detected among the top 50 positions in Freedman et al. [19] and in Yeri et al.
[21], respectively. The most abundant miRNA in Freedman et al was hsa-miR-451a, while in
our sample set this miRNA was found in the 5th position. According to public data deposited
in the miRmine database [44], hsa-miR-486-5p and hsa-miR-451a are the two most abundant
miRNAs in plasma, and are produced by red blood cells [39]. Hsa-miR-122, which is highly
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abundant in plasma, is mostly expressed in liver and enters easily into circulation, pointing
towards its potential as biomarker for several liver pathologies [45].
In agreement with Freedman et al. [19] and Yeri et al. [21] we also found piRNAs, tRNAs,
snoRNAs, snRNAs, VTRNAs and lncRNAs in plasma. The abundance of miRNAs, tRNAs,
snoRNAs, snRNAs, and VTRNAs was in a similar range among previous studies. In contrast,
there were strong discrepancies in the piRNA levels. Interestingly, a piRNA cluster mapping to
several piRNAs and RXRB gene accounted for 37.94% of the reads in the plasma samples ana-
lysed in this study. After visual inspection of the genomic region, we realized that this cluster
also overlaps with Y RNA genes (RNAY4/RNAY4P10). Indeed, Yeri et al. (2017) described a
high proportion of sequences mapping to Y RNA in plasma (>60%) and a much lower abun-
dance of piRNAs [21] Y RNAs participate in chromosomal DNA replication and are involved
in RNA stability and response to stress [46]. Circulating Y RNAs of 25–33 nt have been found
in blood, within vesicles or as cell-free ribonucleoprotein (RNP) complexes [47–49]. Their
function in biofluids, if any, is unknown and it cannot be discarded whether they are degrada-
tion products.
piRNAs were thought to be specific to germ cells, where they play essential roles in fertility
and regeneration [50], but they have been described in plasma [19, 21], urine, and saliva [21]
and in healthy and cancer somatic cells [51, 52]. In particular, Keam et al showed that Hiwi2
protein, one of the three human Piwi proteins, was ubiquitously expressed in somatic cells.
The sequencing of the RNA co-immunoprecipitated with Hiwi2 protein identified a wide
range of small RNA sequences of 18 to 34 nt that mapped to processed tRNA fragments,
known piRNAs and coding genes, among others. The authors suggest that, in somatic cells,
the Piwi-piRNA pathway participates in the regulation of protein translation [51]. Of note, the
way how piRNAs are identified, through sequencing of Piwi bound RNAs, might introduce
some noise in the piRNA sequence pool in reference databases.
Differences in small RNA abundance with previous publications [19, 21] can be explained
by biological and technical factors. The quantification of small RNAs was performed using dif-
ferent NGS platforms, for which some bias to specific small RNAs have been described before
[20]. Moreover, these studies used different bioinformatics pipelines. The small sample size of
our dataset (5 plasma samples) in combination with the low and highly heterogeneous expres-
sion pattern of small RNAs in plasma with only a few of them detected in all samples might
have biased our findings. Finally, our study included a highly specific population of post-par-
tum mothers, while Freedman et al. and Yeri et al. enrolled participants from the general pop-
ulation and male athletes, respectively.
Small RNAs in milk
Several studies have analysed miRNAs in different milk fractions (whole milk [53], skim milk
[38, 54, 55], milk fat [38, 53, 55], or milk extracellular vesicles [56–58]), in different lactation
points, and using different methods (NGS [53, 56, 58], qPCR [55, 57], or microarrays [54]).
Long non-coding RNAs in milk microvesicles have also been reported [57].
In the present study focusing on skim milk, 10 miRNAs accounted for>70% of the reads
mapped to miRNAs. Hsa-miR-148a-3p represented around 30% of the reads. This miRNA
was previously reported to be an abundant miRNA in human milk fat [53] and milk exo-
somes/microvesicles [56, 58]. Of notice, this miRNA was only found in studies using NGS, but
not those applying qPCR or microarrays. Hsa-miR-146b, hsa-miR-200c and hsa-30a-5p,
among top miRNAs expressed in our sample set, were also reported to be highly abundant in
milk fat, skim milk or milk exosomes/microvesicles [53, 55, 56, 58]. Moreover, some of them
were also abundant in the milk cellular fractions [55]. A direct comparison of this study versus
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PLOS ONE | https://doi.org/10.1371/journal.pone.0193527 March 5, 2018 12 / 19
previous publications is subjected to the differences in starting biological material, lactation
period, and quantification methods.
Besides miRNAs, we detected other small RNAs, being tRNAs one of the most abundant
class. tRNAs have been found before in several biofluids [19, 21], including milk exosomes [56,
58]. tRNA fragments seem to have distinct expression patterns and regulatory functions [59].
As far as we know, this is the first study describing the presence of piRNAs, snRNAs, snoRNAs
and VTRNAs in milk. Whether breast milk tRNAs and other small RNAs can reach child cir-
culation and modulate child physiology is of great interest and requires further investigation.
Differential detection of RNAs in both biofluids
As expected, we observed a clear separation between biofluids in terms of their small RNA pro-
file [21, 60]. Previous studies have shown that the miRNA profile observed in each biofluid
recapitulates the miRNA profile of the main cell types releasing small RNAs in those biofluids
(blood cells in plasma [39] and mammary epithelial cells in milk [55]).
Besides miRNAs, several small RNA clusters showed a different expression pattern between
biofluids. As an example, levels of VTRNA2-1were higher in plasma than in milk. VTRNA2-1
transcript is a putative tumour suppressor and modulator of innate immunity, which responds
to environmental stressors during development through loss of imprinting [61]. HOTAIR, also
detected at higher levels in plasma, is a long non-coding RNA that represses transcription of
HOXD genes in trans. HOTAIR has been implicated in cancer [62]. We detected >10,000 iso-
miRs which beard one or several editions (3’ addition, 3’ trimming or 5’ trimming): 4,760 in
plasma and 10,541 in milk, processed from 707 and 875 miRNAs, respectively. Differentially
isomiRs found in milk and plasma matched with the differentially expressed miRNAs detected
in these two biofluids. Some studies suggest that specific isoforms of the same miRNA are the
ones that have an effect on disease [63]. Further investigation is needed to corroborate whether
isomiRs affected by specific diseases can be found in circulation, however our study shows a
myriad of isomiRs which could be potentially used as biomarkers.
Although sequencing depth of milk and plasma samples was similar, the proportion of
good quality reads mapping to miRNA was much higher in milk than in plasma. This could
bias the results of the differential analysis (i.e. some miRNAs expressed at mid or low levels
in milk might not have been detected in plasma due to the lower sequencing depth). DESeq2
normalizes using the geometric median of the ratio between the gene of each sample and the
average among samples, but when there are important differences in library size, normaliza-
tion methods might not to be sufficient [64]. To confirm the biofluid-specific findings, we
applied a subsampling approach in the miRNAs analysis. This approach consists in a ran-
dom selection of the same read number in all the samples of the study. To control for a
potential selection bias, we performed ten random subsamplings. Approximately 60% (186
out of 308) of the miRNAs detected in the main differential analysis were confirmed in the
subsampling analysis. miRNAs only detected in the main analysis and not in the subsam-
pling analysis could be false positives resulting from the different depth of sequencing
between biofluids.
Summary
Plasma and milk samples showed a completely different small RNA profile. Several types of
small RNA species were detected in both biofluids, including miRNAs, tRNAs, snRNAs, snoR-
NAs, lncRNAs, and piRNAs. The presence of different species of small RNAs in biofluids,
besides miRNAs, opens the door to explore them as potential biomarkers of disease or as
mediators of lactation health effects.
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Supporting information
S1 Fig. Bioinformatic and statistical analysis pipeline.
(TIF)
S2 Fig. Bioanalyzer RNA pattern for representative samples. Plasma (A) and milk (B–low
cell contamination, C–potential cell contamination) samples.
(TIF)
S3 Fig. miRNA complexity per sample. miRNA complexity is defined as the number of
miRNA genes that are observed as a function of the number of miRNA reads. The x-axis repre-
sents the number of reads (the total number is indicated on the right). The gradient colour of
the bar from white to black shows the incremental detection of distinct miRNA genes as more
of the sequenced reads are considered.
(TIF)
S4 Fig. Principal Component Analysis of normalized miRNA count data (10 milk and 5
plasma samples). A) Heat-map of the association between the first five principal components
and the technical and biological variables. SAMPLE_TYPE and STARTING_RNA (RNA
input for library preparation, which is related to SAMPLE_TYPE) are strongly associated with
the first principal component having both a p-value of association of 8.44e-08. B) Accumulated
variance explained by the first 10 principal components. In green, the bars corresponding to
principal component one and two are highlighted. The sea-green line indicates the accumu-
lated explained variance in each principal component. The dark-red dashed lines indicate the
principal component which accumulated explained variance overload 90%, which corresponds
to the ninth principal component with an explained variance of 90.82%. C) Scatter plot of the
samples located on the two first principal components. Samples cluster in two groups corre-
sponding to milk (red) and plasma (blue).
(TIF)
S5 Fig. Principal Component Analysis of normalized isomiRs count data (10 milk and 5
plasma samples). A) Heat-map of the association between the first five principal components
and the technical and biological variables. SAMPLE_TYPE and STARTING_RNA (RNA
input for library preparation, which is related to SAMPLE_TYPE) are strongly associated with
the first principal component having both a p-value of association of 0.002. B) Accumulated
variance explained by the first 10 principal components. In green, the bars corresponding to
principal component one and two are highlighted. The sea-green line indicates the accumu-
lated explained variance in each principal component. The dark-red dashed lines indicate the
principal component which accumulated explained variance overload 90%, which corresponds
to the tenth principal component with an explained variance of 92.86%. C) Scatter plot of the
samples located on the two first principal components. Samples cluster in two groups corre-
sponds to milk (red) and plasma (blue).
(TIF)
S6 Fig. Principal Component Analysis of normalized small RNA clusters count data (10
milk and 5 plasma samples). A) Heat-map of the association between the first five principal
components and the technical and biological variables. SAMPLE_TYPE and STARTING_
RNA (RNA input for library preparation, which is related to SAMPLE_TYPE) are highly asso-
ciated with the first principal component having both a p-value of association of 1.52e-07. B)
Accumulated variance explained by the first 10 principal components. In green, the bars corre-
sponding to principal component one and two are highlighted. The sea-green line indicates
the accumulated explained variance in each principal component. The dark-red dashed lines
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indicate the principal component which accumulated explained variance overload 90%, which
corresponds to the seventh principal component with an explained variance of 91.04%. C)
Scatter plot of the samples located on the first two principal components. Samples cluster in
two groups corresponding to milk (red) and plasma (blue).
(TIF)
S7 Fig. Venn diagrams of overlapped differentially expressed miRNAs according to differ-
ent filtering strategies.
(TIF)
S8 Fig. Dendogram of miRNA expression levels in milk and plasma subsamples. For each
sample (10 milk and 5 plasmas) 10 random subsamples of 0.2M reads of miRNA were
obtained. Samples classify by biofluid and by sample of origin. Coloured branches represent 10
subsamples of the same sample of origin and bottom boxes the biofluid.
(TIF)
S9 Fig. Abundance profile along precursor for main RNA clusters detected in milk and
plasma. Y-axis represents the abundance profile, and x-axis the positions in the precursor. A)
Milk: MIR148A, B) Milk: tRNA-Gly-GCC and tRNA-Gly-CCC; C) Plasma: Several piRNAs
and RXRB gene; D) Plasma: MIR486-1,MIR486-2, and ANK1 gene. In orange milk samples,
and in blue plasma samples.
(TIF)
S10 Fig. Abundance profile along precursor for a set of representative small RNA clusters
differentially expressed in milk and plasma. Y-axis represents the abundance profile, and x-
axis the positions in the precursor. A) HOTAIR, higher levels in plasma, B) SNORD95, higher
levels in plasma; C) tRNA-Trp-CCA-2-1, higher levels in milk; D) VTRNA2-1, higher levels in
plasma. In orange milk samples, and in blue plasma samples.
(TIF)
S1 Table. RNA concentration (ng/ml) and purity, by sample.
(XLSX)
S2 Table. Quality control and mapped reads [mean and (SD)] in different species of small
RNAs, by sample.
(XLSX)
S3 Table. Relative abundance of miRNAs in plasma and milk.
(XLSX)
S4 Table. Differential detection of miRNAs by biofluid—ordered by p value.
(XLSX)
S5 Table. Relative abundance of isomiRs in plasma and milk.
(XLS)
S6 Table. Differential detection of isomiRs by biofluid—ordered by p value.
(XLS)
S7 Table. Relative abundance of small RNA clusters in plasma and milk.
(XLSX)
S8 Table. Differential detection of RNA clusters by biofluid—ordered by p value.
(XLSX)
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